Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2011

View Archived Issues

New epigenetic therapy for aggressive leukemia shows promise in vivo

Novel target and agents explored for treating hypertension

Presentations provide further phase II data on lesinurad in gout

Abatacept shows efficacy in subgroup of patients with lupus nephritis

New beta-secretase 1 inhibitors disclosed by Array BioPharma and Genentech

GLCCI1 gene variants linked to response to inhaled glucocorticoid asthma therapy

Novel kinesin-like protein KIF11 inhibitors presented

Scientists present new MAP kinase p38 inhibitors

Dainippon Sumitomo Pharma reviews activities of second quarter of fiscal year 2011

University of North Carolina team patents novel anisamide-oligonucleotide conjugates

LivTech and Yakult Honsha enter option agreement for LIV-2008 anticancer program

Gilead Sciences and the Cardiovascular Research Foundation start new ranolazine trial

Novel vaccines for human cytomegalovirus infection prepared in Germany

Taisho Pharmaceutical recaps events of second quarter of fiscal year 2011

Corimmun discloses new fusion proteins for cardiovascular diseases

NeurogesX reports encouraging results on NGX-1998 in postherpetic neuralgia

EC grants marketing authorization to orphan drug for adrenal insufficiency in adults

Lilly and Amylin reach agreement to terminate diabetes alliance

Ablynx and Merck Serono enter new Nanobodies collaboration

Salix Pharmaceuticals to acquire Oceana Therapeutics

FDA approves Erbitux for new indication

FDA accepts NDA for vismodegib

Gen-Probe files notice relating to FDA review of Progensa PCA3 assay

Opexa Therapeutics' lead product receives FDA fast track status

BARDA awards contract to RxBio to develop radiomitigant countermeasure drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...